$PLSM

Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring

Pulsenmore (NASDAQ: PLSM, TASE: PLSM) announced its home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov in Israel, expanding access to at-home pregnancy monitoring. This move broadens the company's presence in central Israel and supports its hybrid monitoring model, combining hospital and at-home care. Pulsenmore's technology aims to improve maternal health by enabling remote ultrasound scans under medical guidance.

Original reporting
Published Aug 19, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring — source image
Decision brief

The 30-second read

$PLSMNeutralLow
01

Why it matters

The new hospital integration expands the company's service network but lacks disclosed financial magnitude, suggesting modest market impact.

02

Market read

Operational expansion with limited immediate trading relevance; may be a longer‑term growth catalyst.

03

What to watch

Potential regulatory approvals and reimbursement pathways in Israel could affect rollout speed.

Relevance 4/10Novelty 5/10Timing: today

Background

Pulsenmore develops home-use ultrasound devices that connect patients with clinicians remotely, aiming to improve prenatal care access.

Company-level read

Ticker impact

$PLSMNeutralMedium confidence
Context

Pulsenmore announced the integration of its home ultrasound technology at Ichilov's Lis Maternity Hospital, expanding its Israeli footprint.

Expected impact

Limited short-term price movement; potential modest upside if rollout accelerates revenue growth.

Evidence & confidence

No disclosed revenue impact or funding; the news is primarily operational expansion.

Market effects

Highlights growing interest in at‑home diagnostic devices within the med‑tech sector.

May encourage Israeli hospitals to consider similar tele‑ultrasound solutions.

Limited; primarily relevant to niche maternal‑health technology investors.

Counterpoint

The expansion may strain Pulsenmore's resources without delivering immediate revenue, risking dilution of focus.

Key entities

  • Pulsenmore Ltd.

    Developer of home ultrasound solutions.

  • Lis Maternity and Women's Hospital (Ichilov)

    Major Israeli maternity hospital adopting the technology.

Related articles

$PLSMMed

Pulsenmore stock surges 160% on Israel AI program selection By Investing.com

Pulsenmore Ltd. (NASDAQ:PLSM) shares jumped about 160% after the company said it was selected for Israel’s Healthcare AI Regulatory Sandbox Program by the Israel Innovation Authority and Ministry of Health. Pulsenmore will receive funding for a $1 million project to develop and clinically validate AI for its home ultrasound platform, with Beilinson Hospital/Clalit Health Services.

$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

$MRKMedAI 8/10

Jarvis: A cancer vaccine is closer than ever

Merck & Co. and Moderna Inc. reported positive late-stage trial results for their mRNA cancer vaccine, intismeran, combined with Keytruda, showing extended time before melanoma recurrence. Moderna's stock more than doubled. Full data pending.

$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

$METAMed

Sourced Its Most Powerful AI Model to Take on OpenAI and Anthropic. Should Investors Watch Meta's AI Spending Closely?

Meta Platforms (META) is investing heavily in AI to improve ad conversions on Facebook and Instagram, with capital expenditures expected to reach $130B-$145B by 2026. The company released AI models like Muse Glimmer and plans to monetize AI through better user engagement and targeted advertising. Q2 results showed an 8.3% increase in Facebook ad clicks and a 15.7% rise in ad conversions. However, high spending could pressure future profit margins.